Neratinib

Major

Neratinib Ranolazine Aspruzyo Increased ranolazine exposure and an increased CYP3A4 substrate exposure Details Neratinib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Neratinib Repotrectinib Augtyro Increased repotrectinib exposure, an increased risk of repotrectinib-related adverse effects, reduced CYP3A4 substrates exposure a... Details Neratinib Ribociclib Kisqali Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Neratinib Rifampin Rifadin Decreased exposure of neratinib and active metabolites and risk of reduced efficacy Details Neratinib Ritonavir Norvir Increased neratinib exposure and risk of toxicity Details Neratinib Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Neratinib Saquinavir Increased neratinib exposure and risk of toxicity Details Neratinib Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Neratinib Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Neratinib Sirolimus Felycin Increased exposure to P-gp substrate and risk of toxicity Details Neratinib Sodium Bicarbonate Alka-Seltzer® Heartburn Decreased neratinib exposure Details Neratinib Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Neratinib St John's Wort Decreased exposure of neratinib and active metabolites and risk of reduced efficacy Details Neratinib Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Neratinib Tacrolimus Astagraf Increased exposure to P-gp substrate and risk of toxicity Details Neratinib Taurursodiol Decreased exposure of the CYP3A4 substrate Details Neratinib Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Neratinib Telaprevir Increased neratinib exposure and risk of toxicity Details Neratinib Telithromycin Increased neratinib exposure and risk of toxicity Details Neratinib Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Neratinib Tolvaptan Jynarque Increased exposure to P-gp substrate and risk of toxicity Details Neratinib Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Neratinib Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Neratinib Tucatinib Tukysa Increased exposure to CYP3A substrate and risk of toxicity Details Neratinib Venetoclax Venclexta Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Neratinib Verapamil Calan Increased neratinib exposure and risk of toxicity Details Neratinib Vonoprazan Voquezna Increased CYP3A substrates exposure Details Neratinib Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Neratinib Voriconazole Vfend Increased neratinib exposure and risk of toxicity Details Neratinib Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details

Moderate

Neratinib Levothyroxine Ermeza Increased risk of hypothyroidism Details Neratinib Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Neratinib Kratom Increased CYP3A substrate exposure Details Neratinib Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Neratinib Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Neratinib Tenofovir Alafenamide Increased tenofovir alafenamide exposure and an increased risk of tenofovir alafenamide-related adverse effects Details